gemcitabine has been researched along with vorinostat in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Gately, S; Gonzales, P; Sepulveda, M; Wang, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Arkus, N; Arnold, NB; Gunn, J; Korc, M | 1 |
| Chun, SG; Yee, NS; Zhou, W | 1 |
| Freeman, JW; Giles, FJ; Wang, Y | 1 |
| Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
| Hassan, R; Kelly, RJ; Sharon, E | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C | 1 |
| Choi, EK; Hong, SW; Hong, YS; Hwang, IY; Jin, DH; Kim, JE; Kim, JH; Kim, KP; Kim, SM; Kim, TW; Lee, DH; Lee, EY; Lee, JS; Lee, WK; Moon, JH; Park, SJ; Shin, JS; Shin, YJ | 1 |
| Duvic, M | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Connelly, JW; Doroshow, JH; Fang, J; Fogli, LK; Hamed, H; Harris, E; Hose, C; Konaté, MM; Krushkal, J; Li, MC; Miller, SB; Monks, A; Palmisano, A; Polley, EC; Rapisarda, A; Simon, R; Simpson, MA; Sonkin, D; Teicher, BA; Voth, AR; Wu, X; Zhao, Y | 1 |
| Ahmed, AA; Neidle, S | 1 |
3 review(s) available for gemcitabine and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy; Folic Acid Antagonists; Gemcitabine; Genetic Therapy; Glutamates; Guanine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunotherapy; Mesothelioma; Molecular Targeted Therapy; Pemetrexed; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine; Vorinostat | 2011 |
Systematic review of combination therapies for mycosis fungoides.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2014 |
2 trial(s) available for gemcitabine and vorinostat
| Article | Year |
|---|---|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Vorinostat | 2015 |
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hydroxamic Acids; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Vorinostat | 2015 |
15 other study(ies) available for gemcitabine and vorinostat
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Neoplasms; Pancreas; Pancreatic Neoplasms; Structure-Activity Relationship | 2013 |
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Lung Neoplasms; NF-kappa B; Transcription, Genetic; Vorinostat | 2005 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Deoxycytidine; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Up-Regulation; Vorinostat | 2007 |
Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Tumor Stem Cell Assay; Vorinostat | 2009 |
Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Vorinostat | 2009 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Vorinostat | 2016 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cladribine; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Hematopoietic Stem Cell Transplantation; Histones; Humans; Hydroxamic Acids; Intracellular Membranes; Lymphoma; Mitochondria; Signal Transduction; Transplantation Conditioning; Vorinostat | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Early Growth Response Protein 1; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Internet; National Cancer Institute (U.S.); Oligonucleotide Array Sequence Analysis; Signal Transduction; Translational Research, Biomedical; United States; Vorinostat | 2018 |
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; G-Quadruplexes; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Small Molecule Libraries; Vorinostat | 2020 |